EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Endocrine crosstalk in cardiovascular-kidney-metabolic syndrome-related heart failure: the fibroblast growth factor 23-Klotho axis and cardiometabolic therapy

Dan Sun, Xingjia Wang, He Wang, Zhiyi Shen, Xiangxu Meng, Yabin Zhou

Frontiers in Endocrinology · 2026

DOI: 10.3389/fendo.2026.1933732 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Endocrinology, 2026. Verfasst von Dan Sun und 5 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China. Hauptthemen laut MEDLINE: Klotho Proteins, Heart Failure, Fibroblast Growth Factors, Metabolic Syndrome. Die Arbeit nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Heart failure arising in cardiovascular-kidney-metabolic (CKM) syndrome, hereafter referred to as CKM-related heart failure (CKM-HF), is increasingly understood as the cardiac expression of multisystem endocrine and metabolic stress rather than as an isolated myocardial disorder. In this narrative review, we examine how kidney, bone, adipose tissue, gut, pancreas, vasculature, and myocardium communicate through maladaptive hormonal and metabolic signals, with particular emphasis on heart failure with preserved ejection fraction (HFpEF). We position the fibroblast growth factor 23 (FGF23)-Klotho axis as a candidate organizing framework for mineral endocrine stress in diabetic kidney disease and chronic kidney disease. Human observational studies associate higher circulating FGF23 and altered Klotho biology with adverse cardiovascular phenotypes, whereas preclinical studies provide mechanistic plausibility for links to cardiac hypertrophy and fibrosis. However, current evidence does not establish that elevated FGF23 directly causes cardiac remodeling in humans. We examine insulin resistance, adipose dysfunction, RAAS activation, anemia, and gut-derived metabolites selectively as modifiers, competing pathways, or confounders that shape the interpretation of FGF23-Klotho biology in CKM-related heart failure. Established cardiometabolic therapies are discussed according to their proven clinical effects and as modifiers of the context in which FGF23 and soluble Klotho are interpreted; their efficacy is not considered evidence of FGF23-Klotho pathway engagement or mediation. An FGF23-Klotho-centered CKM-HF framework may support research phenotyping, prospective biomarker validation, and mechanism-based trial design. However, the proposed phenotype remains unvalidated, circulating FGF23 and soluble Klotho are not established for routine clinical use, and their incremental value beyond conventional kidney, mineral, cardiac, and imaging markers remains unknown.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Klotho ProteinsHeart FailureFibroblast Growth FactorsMetabolic SyndromeGlucuronidaseCardio-Renal SyndromeHumansFibroblast Growth Factor-23Animals

Stichwörter der Autor:innen

FGF23Klothocardiometabolic therapycardiovascular-kidney-metabolic syndromechronic kidney diseasediabetic kidney diseaseheart failure with preserved ejection fractionmineral metabolism

Substanzen

Klotho ProteinsFibroblast Growth Factor-23FGF23 protein, humanFibroblast Growth FactorsKL protein, humanGlucuronidase

Autor:innen und Institutionen

  • Graduate School, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China.
  • The First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China.
  • The First School of Clinical Medicine, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China.

Zitieren

APA

Sun, D., Wang, X., Wang, H., Shen, Z., Meng, X., & Zhou, Y. (2026). Endocrine crosstalk in cardiovascular-kidney-metabolic syndrome-related heart failure: the fibroblast growth factor 23-Klotho axis and cardiometabolic therapy. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2026.1933732

Vancouver

Sun D, Wang X, Wang H, Shen Z, Meng X, Zhou Y. Endocrine crosstalk in cardiovascular-kidney-metabolic syndrome-related heart failure: the fibroblast growth factor 23-Klotho axis and cardiometabolic therapy. Frontiers in Endocrinology. 2026. doi:10.3389/fendo.2026.1933732

BibTeX
@article{Sun2026,
  author = {Sun, Dan and Wang, Xingjia and Wang, He and Shen, Zhiyi and Meng, Xiangxu and Zhou, Yabin},
  title = {Endocrine crosstalk in cardiovascular-kidney-metabolic syndrome-related heart failure: the fibroblast growth factor 23-Klotho axis and cardiometabolic therapy},
  journal = {Frontiers in Endocrinology},
  year = {2026},
  doi = {10.3389/fendo.2026.1933732}
}
Kostenlos starten →